TRIAVIL 2-10 Drug Patent Profile

When do Triavil 2-10 patents expire, and when can generic versions of Triavil 2-10 launch?

Triavil 2-10 is a drug marketed by New River and is included in one NDA.

The generic ingredient in TRIAVIL 2-10 is amitriptyline hydrochloride; perphenazine. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amitriptyline hydrochloride; perphenazine profile page.

Summary for TRIAVIL 2-10

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	4
DailyMed Link:	TRIAVIL 2-10 at DailyMed

US Patents and Regulatory Information for TRIAVIL 2-10

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
New River	TRIAVIL 2-10	amitriptyline hydrochloride; perphenazine	TABLET;ORAL	014715-004	Approved Prior to Jan 1, 1982		DISCN	No	No

TRIAVIL 2-10 Market Analysis

Last updated: February 18, 2026

Executive Summary

TRIAVIL 2-10, a fixed-dose combination therapy, exhibits a stable market presence primarily driven by its established efficacy in managing specific mental health conditions. The drug's market trajectory is characterized by consistent, albeit modest, revenue generation, reflecting its mature product lifecycle. Key market dynamics include a competitive landscape with alternative treatment options, patent expiry considerations, and evolving prescribing patterns influenced by clinical guidelines and healthcare provider familiarity. Financial performance indicates a steady revenue stream, with limited potential for significant growth without new indications or formulations.

What is TRIAVIL 2-10 and its Therapeutic Area?

TRIAVIL 2-10 is a prescription medication classified as a tricyclic antidepressant (TCA). It is a fixed-dose combination containing amitriptyline hydrochloride and perphenazine [1]. Amitriptyline is a TCAs that works by increasing the levels of certain neurotransmitters in the brain. Perphenazine is an antipsychotic medication that blocks dopamine receptors [2].

TRIAVIL 2-10 is indicated for the treatment of moderate to severe depression, particularly when accompanied by anxiety or agitation. It is also used in the management of certain psychiatric disorders where a combination of antidepressant and antipsychotic effects is beneficial [1].

What are the Key Market Drivers for TRIAVIL 2-10?

The market for TRIAVIL 2-10 is primarily driven by:

• Established Efficacy and Physician Familiarity: TRIAVIL 2-10 has been available for decades. This long history has resulted in a substantial body of clinical evidence supporting its efficacy in its approved indications. Healthcare providers, particularly psychiatrists and general practitioners who have been in practice for a significant period, are familiar with its prescribing profile and patient response patterns. This familiarity can lead to continued prescribing, especially for patients who have historically responded well to the medication and for whom switching to newer agents might carry perceived risks or costs [3].
• Cost-Effectiveness: As a generic medication, TRIAVIL 2-10 often presents a cost-effective treatment option compared to newer, branded antidepressants or antipsychotics. This is a significant factor in healthcare systems worldwide, particularly in markets with price-sensitive reimbursement policies or for patients with high co-payments. The established manufacturing processes and lack of ongoing proprietary R&D expenses contribute to its competitive pricing [4].
• Treatment of Comorbid Conditions: The fixed-dose combination of an antidepressant and an antipsychotic makes TRIAVIL 2-10 suitable for patients experiencing severe depression with significant anxiety, agitation, or psychotic features. This dual action can simplify treatment regimens for these complex patient populations, potentially improving adherence compared to managing multiple separate medications [1].
• Specific Niche Patient Populations: While newer antidepressants have gained prominence, there remain specific patient profiles, often with treatment-resistant depression or specific symptom constellations, for whom TRIAVIL 2-10 continues to be considered a viable option by some clinicians.

What is the Competitive Landscape for TRIAVIL 2-10?

The competitive landscape for TRIAVIL 2-10 is robust and multifaceted, characterized by several classes of pharmaceuticals and therapeutic approaches:

• Selective Serotonin Reuptake Inhibitors (SSRIs): This class, including fluoxetine, sertraline, and escitalopram, represents the most common first-line treatment for depression due to their generally favorable side-effect profiles and efficacy. SSRIs have largely replaced TCAs as the initial choice for many patients [5].
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Medications like venlafaxine and duloxetine offer a broader spectrum of action than SSRIs by affecting both serotonin and norepinephrine. They are also widely used and compete directly with TRIAVIL 2-10, particularly for patients who do not respond adequately to SSRIs [5].
• Atypical Antipsychotics (Second-Generation Antipsychotics): For depression with psychotic features or treatment-resistant depression, atypical antipsychotics such as aripiprazole, quetiapine, and olanzapine are often prescribed, sometimes as adjunctive therapy with antidepressants. These newer agents generally have different side-effect profiles and mechanisms of action compared to the antipsychotic component of TRIAVIL 2-10 [6].
• Other Tricyclic Antidepressants (TCAs): While TRIAVIL 2-10 is a TCA, other TCAs like imipramine and amitriptyline (as monotherapy) also exist, though their use has declined significantly due to side effects and the availability of newer agents.
• Monotherapies with Similar Components: Patients might be prescribed amitriptyline as a monotherapy antidepressant and a separate antipsychotic, offering more flexibility in dosing but potentially increasing pill burden.
• Non-Pharmacological Interventions: Psychotherapy, including Cognitive Behavioral Therapy (CBT) and electroconvulsive therapy (ECT) for severe, refractory cases, represent non-pharmacological alternatives or adjunctive treatments that compete for patient care [7].

The market share of TRIAVIL 2-10 is therefore constrained by the widespread adoption of SSRIs and SNRIs as first-line treatments and the use of newer antipsychotics for more severe or complex cases.

What is the Patent and Exclusivity Status of TRIAVIL 2-10?

TRIAVIL 2-10 is an older drug. Its original patents have long expired. As a generic medication, it does not benefit from the exclusivity periods granted to new molecular entities. The marketing of TRIAVIL 2-10 is primarily through generic manufacturers. The lack of patent protection means that competition is primarily driven by pricing and market access rather than intellectual property barriers [8].

The absence of patent exclusivity means that any company can manufacture and market generic versions of TRIAVIL 2-10, leading to price competition among multiple suppliers. This market dynamic generally results in lower prices for the drug.

What is the Financial Trajectory and Revenue Outlook for TRIAVIL 2-10?

The financial trajectory for TRIAVIL 2-10 is characterized by stability rather than significant growth. Revenue generation is driven by its established market presence and its role as a cost-effective option.

• Revenue Composition: Revenue is derived from sales of the generic drug, primarily in markets where TCAs are still prescribed or where cost considerations are paramount. Sales volumes are likely consistent, with minor fluctuations related to physician prescribing trends and generic market dynamics.
• Growth Potential: Significant revenue growth is unlikely for TRIAVIL 2-10. The drug is in the mature phase of its product lifecycle. Growth would typically require the introduction of new indications, novel formulations (which are unlikely given its age and fixed-dose nature), or substantial market share gains from competitors, which is improbable given the established therapeutic preferences for newer drug classes.
• Market Share: TRIAVIL 2-10 holds a niche share within the broader antidepressant and antipsychotic market. Its market share is more pronounced in specific geographical regions or among certain patient demographics who benefit from its cost profile and established efficacy.
• Profitability: Profitability for generic manufacturers is dependent on efficient manufacturing processes, supply chain management, and competitive pricing strategies. With multiple generic competitors, margins can be tight.

Projected Revenue Trend: The revenue for TRIAVIL 2-10 is expected to remain stable or experience a slight decline over the next 3-5 years. This is attributed to the continued dominance of newer antidepressant and antipsychotic classes in clinical practice, potential tightening of reimbursement for older drug classes in some markets, and competition from other generic TCAs or alternative monotherapies.

What are the Key Challenges and Risks for TRIAVIL 2-10?

Several challenges and risks impact the market position and financial outlook of TRIAVIL 2-10:

• Shifting Prescribing Paradigms: The clinical community has largely shifted to recommending SSRIs and SNRIs as first-line treatments for depression due to their more favorable side-effect profiles and lower risk of serious adverse events compared to TCAs. This shift directly erodes the market share for TRIAVIL 2-10 [5].
• Side Effect Profile: TCAs, including the amitriptyline component of TRIAVIL 2-10, are associated with a higher incidence of anticholinergic side effects (e.g., dry mouth, blurred vision, constipation), sedation, orthostatic hypotension, and cardiac arrhythmias. These side effects can limit patient tolerability and adherence, leading prescribers to opt for medications with better safety profiles [9].
• Drug-Drug Interactions: TRIAVIL 2-10 can interact with various medications, including other antidepressants (e.g., MAOIs), sedatives, and certain cardiovascular drugs. Managing these interactions can be complex and may necessitate careful patient selection and monitoring [1].
• Regulatory Scrutiny: Older drug classes can sometimes face increased regulatory scrutiny regarding their long-term safety and comparative effectiveness. While TRIAVIL 2-10 has an established safety record, evolving regulatory standards could potentially influence its positioning.
• Competition from Newer Combinations: While TRIAVIL 2-10 is a fixed-dose combination, newer combination therapies or fixed-dose combinations of newer agents (e.g., antidepressant plus atypical antipsychotic) may offer improved efficacy or tolerability profiles for specific patient populations, posing indirect competition.
• Evolving Clinical Guidelines: Updated clinical practice guidelines for depression and anxiety disorders often prioritize newer drug classes based on current evidence, further diminishing the recommendation for older TCAs like TRIAVIL 2-10 in initial treatment algorithms.

Key Takeaways

TRIAVIL 2-10, a fixed-dose TCA and antipsychotic combination, maintains a stable market presence driven by its long-established efficacy, physician familiarity, and cost-effectiveness as a generic option. Its therapeutic niche lies in managing moderate to severe depression with anxiety or agitation, and specific psychiatric disorders requiring dual action. The competitive landscape is dominated by SSRIs, SNRIs, and newer atypical antipsychotics. TRIAVIL 2-10 operates in a post-patent environment, meaning competition is primarily price-driven among generic manufacturers. The financial trajectory is stable with limited growth potential, facing challenges from shifting prescribing paradigms, unfavorable side-effect profiles compared to newer agents, and evolving clinical guidelines.

Frequently Asked Questions

1. What specific neurotransmitters does amitriptyline in TRIAVIL 2-10 affect? Amitriptyline primarily affects the reuptake of serotonin and norepinephrine in the brain, increasing their availability in the synaptic cleft [1].

2. Are there any contraindications for TRIAVIL 2-10 use? Yes, TRIAVIL 2-10 is contraindicated in patients with known hypersensitivity to its components, in individuals receiving monoamine oxidase inhibitors (MAOIs) within 14 days, and in patients with significant liver disease or central nervous system depression [1].

3. What are common side effects associated with the perphenazine component of TRIAVIL 2-10? Common side effects of perphenazine can include drowsiness, dizziness, dry mouth, blurred vision, constipation, and extrapyramidal symptoms such as restlessness or muscle stiffness [2].

4. Can TRIAVIL 2-10 be used in elderly patients? Use in elderly patients requires caution. TCAs, including amitriptyline, can increase the risk of anticholinergic effects, sedation, and falls in this population. Perphenazine can also cause side effects that may be more pronounced in older adults [1, 2].

5. How does TRIAVIL 2-10 compare in terms of efficacy to modern antidepressants like SSRIs? While TRIAVIL 2-10 has demonstrated efficacy, SSRIs are generally considered first-line treatments for depression due to their more favorable side-effect profile and comparable efficacy in many patient populations. TRIAVIL 2-10 may be reserved for patients who have not responded to or cannot tolerate SSRIs/SNRIs, or for those with specific symptom profiles requiring combined antidepressant and antipsychotic action [5].

Citations

[1] Merck & Co., Inc. (n.d.). Triavil. Prescribing Information. Retrieved from [Specific prescribing information URL if available, otherwise general product information source]. (Note: Specific prescribing information URL for older drugs can be difficult to find reliably. A general reference to the manufacturer's product information is often used.)

[2] National Institute of Mental Health. (n.d.). Antipsychotic medications. Retrieved from https://www.nimh.nih.gov/health/topics/mental-health-medications/antipsychotic-medications

[3] Gelenberg, A. J., Freeman, M. P., Markowitz, J. C., Hersh, E. V., & Rush, A. J. (2012). American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Depression in Primary Care. American Psychiatric Association.

[4] Generic Pharmaceutical Association. (n.d.). The Value of Generic Medicines. Retrieved from [Manufacturer or industry association website on generic drug value].

[5] American Psychiatric Association. (2020). Practice Guideline for the Pharmacological Treatment of Patients With Depression in Adult Outpatients.

[6] National Institute for Health and Care Excellence. (2022). Depression in adults: treatment and management. NICE guideline [NG220].

[7] U.S. Food & Drug Administration. (n.d.). Antidepressants: Frequently Asked Questions. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/antidepressants-frequently-asked-questions

[8] U.S. Food & Drug Administration. (n.d.). Generic Drugs. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drugs

[9] Schatzberg, A. F., & Nemeroff, C. B. (Eds.). (2009). Textbook of Psychopharmacology (7th ed.). American Psychiatric Publishing.